课题基金 / 基金详情

Antigen-independent suppression of ocular angiogenesis via the Fc receptor

Antigen-independent suppression of ocular angiogenesis via the Fc receptor
通过 Fc 受体对眼部血管生成进行抗原非依赖性抑制
批准号:
10192726
负责人:
Jayakrishna Ambati
金额:
$39.16万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-01 至 2023-06-30

项目摘要

项目成果

Jayakrishna Ambati的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Abstract Aberrant angiogenesis, a process of new blood vessel formation, is implicated in a variety of diseases that affect nearly 10% of the world’s population. In new and exciting work, we made the surprising observation that human IgG1, as a class, suppresses multiple models of ocular and non-ocular angiogenesis in mice and cells independent of their actual target. This target- independent angiostatic effect is mediated through FcγRI receptor signaling. Given the abundance of IgG1 proteins in the blood, as well as their widespread therapeutic use, our findings assume broad importance in better understanding the full range of the biological effects of antibodies. The extent and precise mechanisms of IgG/Fc receptor modulation of the vasculature remain to be deciphered. Therefore, it is critical to define the immunological molecular signaling pathways responsible for mediating the angioinhibitory effects of human IgG1/FcγRI ligation. It is also important to delineate the influence of therapeutic FcγRI-binding proteins on the cell types and molecular pathways involved in aberrant angiogenesis. In addition to advancing the fundamental biology of IgG/Fc-mediated angiosuppression, our findings may also address a significant ophthalmic need by improving existing IgG1-containing medicines. To that end, we will determine whether a rationally guided re-dosing or reformulation of bevacizumab, a full-length humanized IgG1 antibody, can substantially improve its therapeutic efficacy by exploiting this newly discovered anti-angiogenic activity, which is separate from VEGFA neutralization. In order to accomplish these goals, we propose to perform detailed studies in models that better mimic the human vascular and immune systems. We will utilize mouse (including humanized) models of corneal and choroidal neovascularization to provide novel functional and molecular insights into how IgG1/FcγRI signaling contributes to modulation of angiogenesis. Findings from this project will help illuminate innovative molecular basis of the vasculature that can be targeted in the multitude of ocular pathologies caused by abnormal vessel growth. As such, this proposal is aligned with the dual goals of the Retinal Diseases and Immunology Programs of NEI's Vision Research: Needs, Gaps, and Opportunities Strategic Plan.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cytosolic SINE retrotransposable element cDNA and mitochondrial DNA in aging retina
  • 批准号:
    10722062
  • 项目类别:
  • 资助金额:
    $62.67万
  • 财政年份:
    2023
  • 负责人:
    Jayakrishna Ambati
  • 依托单位:
Defining the role of SINE retrotransposons and inflammasome activation in Alzheimer's disease
  • 批准号:
    10696066
  • 项目类别:
  • 资助金额:
    $62.08万
  • 财政年份:
    2022
  • 负责人:
    Jayakrishna Ambati
  • 依托单位:
Defining the role of SINE retrotransposons and inflammasome activation in Alzheimer's disease
  • 批准号:
    10517678
  • 项目类别:
  • 资助金额:
    $62.08万
  • 财政年份:
    2022
  • 负责人:
    Jayakrishna Ambati
  • 依托单位:
Nlrp3 inflammasome activation in early diabetic retinopathy - Administrative Supplement ERG Request
  • 批准号:
    10643583
  • 项目类别:
  • 资助金额:
    $5.28万
  • 财政年份:
    2020
  • 负责人:
    Jayakrishna Ambati
  • 依托单位:
海外基金